APA (7th ed.) Citation

XL, W., Y, Z., HY, Z., WF, F., HY, L., MZ, Q., . . . RH, X. (2023). Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. The oncologist, 28(1), e36. https://doi.org/10.1093/oncolo/oyac225

Chicago Style (17th ed.) Citation

XL, Wei, et al. "Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials." The Oncologist 28, no. 1 (2023): e36. https://doi.org/10.1093/oncolo/oyac225.

MLA (9th ed.) Citation

XL, Wei, et al. "Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials." The Oncologist, vol. 28, no. 1, 2023, p. e36, https://doi.org/10.1093/oncolo/oyac225.